PALM INTRANET

Day : Wednesday
Date: 7/14/2004
Time: 11:29:51

Inventor Name Search Result

Your Search was:

Last Name = LILJEGREN
First Name = KEN

Application#	Patent#	Status	Date Filed	Title	Inventor Name 6
60550909	Not Issued	020	03/05/2004	CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM	LILJEGREN, KEN
60308914	Not Issued	159	07/31/2001	CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM	LILJEGREN, KEN
10619743	Not Issued	030	07/01/2003	PHARMACEUTICAL COMPOSITION CONTAINING CITALOPRAM	LILJEGREN, KEN
10403453	Not Issued	041	03/31/2003	CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM	LILJEGREN, KEN
10310621	Not Issued	041	12/05/2002	CRYSTALS OF PHARMACEUTICALLY ACCEPTABLE SALTS OF CITALOPRAM, METHODS OF CRYSTALLIZATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM	LILJEGREN, KEN
09730380	Not Issued	071	12/05/2000	PHARMACEUTICAL COMPOSITION CONTAINING CITALOPRAM	LILJEGREN, KEN

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name Liljegren **First Name** ken

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

09/730,380

STN SEARCH 7-14-04

=> d ibib abs 1-13

L8 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:162680 CAPLUS
DOCUMENT NUMBER: 140:217507
TITLE: Process for the preparation of high-purity citalopram and its pharmaceutically acceptable salts
INVENTOR(S): Muddasani, Pulla Reddy; Nannapaneni, Wenkaiah Chowoary
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016602	A1	20040226	WO 2002-IN167	20020814

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2002-IN167 20020814
OTHER SOURCE(S): CASREACT 140:217507
AB The preparation of high-purity citalopram base and its hydrobromide salt comprises: (1) isolation of crude citalopram base after water work up of the reaction into a nonpolar aromatic or dialkyl ether solvent; (2) extraction of the citalopram base into an aqueous organic acid; (3) neutralization of the acid layer with an organic base to a controlled pH (7.0-8.0); (4) extraction of the pure base into a nonpolar aromatic or dialkyl ether solvent and **crystallization** from the same solvent after concentrating it to a certain volume under reduced pressure; (5) preparation of high purity citalopram hydrobromide in a nonpolar aromatic or dialkyl ether solvent using 40-50% HBr in acetic acid as the HBr source and **crystallizing** it out from the same solvent or an alternatively preparation of the HBr salt in aqueous medium using aqueous HBr and **crystallizing** it out from the same medium at 0-10°; and (6) recrystn. of high-purity citalopram hydrobromide salt of pharmaceutically acceptable grade from a mixture of alc. solvents.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

overlap

L8 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:991182 CAPLUS
DOCUMENT NUMBER: 140:31501
TITLE: **Crystals** of pharmaceutically acceptable salts of citalopram, methods of **crystallization**, and pharmaceutical compositions comprising them
INVENTOR(S): Liljegren, Ken; Holm, Per; Nielsen, Ole; Wagner, Sven
PATENT ASSIGNEE(S): H. Lundbeck A/s, Den.

SOURCE: U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 730,380.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003232881	A1	20031218	US 2002-310621	20021205
US 2003109577	A1	20030612	US 2000-730380	20001205
GB 2376233	A1	20021211	GB 2002-19820	20010731
GB 2376233	B2	20030910		

PRIORITY APPLN. INFO.: DK 2000-1614 A 20001027
US 2000-730380 A2 20001205
DK 2000-1202 A 20000810
GB 2001-18579 A3 20010731

AB A method of **crystallizing** larger particles of citalopram or its hydrochloride or hydrobromide, in a size comparable to the size of the filler which are useful for the manufacture of directly compressed tablets is presented.

L8 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:950850 CAPLUS
DOCUMENT NUMBER: 140:19846
TITLE: Pharmacologically active salts
INVENTOR(S): Larsen, Claus Selch
PATENT ASSIGNEE(S): Danmarks Farmaceutiske Universitet, Den.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099293	A1	20031204	WO 2003-DK343	20030522

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DK 2002-798 A 20020523

AB Novel salts formed between 2 active drug substances, wherein the first drug substance is an NSAID drug substance containing a carboxylic acid group and the second drug substance contains an amine group and is a local anesthetic or selected from the group consisting of nonopioid analgesics, antipsychotics, antidepressants, narcotic antagonists and local anesthetics. Such salts that are poorly soluble in tissue fluids are feasible for injectable prolonged release formulations, where the NSAID addnl. to minimize pain and tissue reaction at the site of administration. Thus, a salt was prepared by the reaction of the free base, bupivacaine with diflunisal in acetone. The solubility and dissoln. profiles of the salt were

determined
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:777773 CAPLUS
DOCUMENT NUMBER: 139:276808
TITLE: Transalification process for the preparation of purified citalopram hydrochloride or hydrobromide
INVENTOR(S): Hamied, Yusuf Khwaja; Kankan, Rajendra N.; Rao, Dharmaraj R.
PATENT ASSIGNEE(S): Cipla Ltd., India; Wain, Christopher Paul
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080589	A1	20031002	WO 2003-GB1032	20030311

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2002-6708 A 20020321
AB Purified citalopram hydrochloride or hydrobromide are made by purifying another different citalopram salt (e.g., citalopram besylate by **crystallization**) and then converting the purified salt to the hydrochloride or hydrobromide.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:752685 CAPLUS
DOCUMENT NUMBER: 139:261161
TITLE: Improved process for the preparation of citalopram and its hydrobromide
INVENTOR(S): Babu, Ambati Narahari; Goud, Vuddamari Srinivas; Gaonkar, Santhosh Laxman; Thomas, Saji D.; Manjunatha, Sulur G.; Kulkami, Ashok Krishna
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1346989	A1	20030924	EP 2002-252047	20020321

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

WO 2003080590 A1 20031002 WO 2003-IB1641 20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2002-252047 A 20020321
OTHER SOURCE(S): CASREACT 139:261161
AB A process for the preparation of citalopram (an anti-depressant drug) comprises the C-alkylation of 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (5-cyanophthalane) with 3-dimethylaminopropyl chloride in the presence of potassium tert.-butoxide. Suitably, the alkylation is carried out in the presence of DMSO (DMSO). The citalopram thereby produced can be isolated as a **crystalline** solid in one step from the reaction mixture by adding an equal volume of a water-miscible solvent, such as iso-Pr alc., to the mixture Citalopram hydrobromide is prepared by treating citalopram (base) with aqueous hydrobromic acid, such as at pH 1-3.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:696079 CAPLUS
DOCUMENT NUMBER: 139:219273
TITLE: Preparation of citalopram salts
INVENTOR(S): Hamied, Yusuf Khwaja; Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra
PATENT ASSIGNEE(S): Cipla Limited, India
SOURCE: Brit. UK Pat. Appl., 7 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2385848	A1	20030903	GB 2002-4683	20020227
WO 2003072563	A1	20030904	WO 2003-GB816	20030226

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 2002-4683 A 20020227
AB Amorphous pharmaceutically acceptable salts of citalopram are made by spray drying, lyophilization or evaporation of solns. and may be incorporated into pharmaceutical compns. Citalopram hydrobromide 20 g, was dissolved in 200 mL methanol and spray dried with an inlet temperature of 110 °C, outlet temperature of 67 °C and feed rate of 5 mL/min to obtain amorphous citalopram hydrobromide.

L8 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:975673 CAPLUS
DOCUMENT NUMBER: 138:24637
TITLE: Preparation of citalopram hydrobromide
INVENTOR(S): Arai, Nobuhiro; Ikemoto, Tetsuya; Iki, Masami
PATENT ASSIGNEE(S): Sumika Fine Chemicals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002371077	A2	20021226	JP 2001-174531	20010608

PRIORITY APPLN. INFO.: JP 2001-174531 20010608
OTHER SOURCE(S): CASREACT 138:24637
AB The title antidepressant is prepared by treating citalopram with HBr in acetone followed by **crystallization** in the presence of citalopram hydrobromide seed **crystals**. Thus, citalopram was dissolved in acetone, treated with HBr, **crystallized** in the presence citalopram hydrobromide seed **crystals** to give 74.8% citalopram hydrobromide.

L8 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:814053 CAPLUS
DOCUMENT NUMBER: 135:348923
TITLE: Citalopram hydrobromide **crystals** and **crystallization**
INVENTOR(S): Ikemoto, Tetsuya; Arai, Nobuhiro; Igi, Masami
PATENT ASSIGNEE(S): Sumika Fine Chemicals Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1152000	A1	20011107	EP 2001-108914	20010410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002020379	A2	20020123	JP 2001-102717	20010330
US 2001049450	A1	20011206	US 2001-824447	20010402
CA 2343543	AA	20011102	CA 2001-2343543	20010409

PRIORITY APPLN. INFO.: JP 2000-133995 A 20000502
AB Citalopram-HBr is dissolved in a solvent containing at least one member selected from the group consisting of alc. having 1-3 carbon atoms, water and acetone is **crystallized** or recrystd. while controlling the cooling rate, thereby to 1) provide an industrial method for **crystallizing** citalopram-HBr, which enables easy control of the **crystal** characteristics, such as particle size, particle size distribution and aspect ratio and the like of the **crystal**, and 2) provide citalopram-HBr **crystal** having **crystal** characteristics useful as a pharmaceutical bulk.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:797983 CAPLUS
DOCUMENT NUMBER: 135:348880
TITLE: Pharmaceutical composition containing citalopram
INVENTOR(S): Liljegren, Ken; Holm, Per; Nielsen, Ole; Wagner, Sven
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080619	A2	20011101	WO 2001-DK520	20010730
WO 2001080619	A3	20020221		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2353693	C	20030722	CA 2001-2353693	20010724
AU 2001079591	A5	20011107	AU 2001-79591	20010730
EP 1318805	A2	20030618	EP 2001-957768	20010730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013250	A	20030624	BR 2001-13250	20010730
JP 2003531153	T2	20031021	JP 2001-577732	20010730
GB 2368014	A1	20020424	GB 2001-18579	20010731
GB 2368014	B2	20040623		
GB 2376233	A1	20021211	GB 2002-19820	20010731
GB 2376233	B2	20030910		
GR 1004193	B2	20030324	GR 2001-100377	20010731
GR 2001100377	A	20020906		
FR 2812811	A1	20020215	FR 2001-10586	20010808
DE 20113195	U1	20011220	DE 2001-20113195	20010809
NO 2001003891	A	20020211	NO 2001-3891	20010809
DE 10139115	A1	20020328	DE 2001-10139115	20010809
ES 2172481	A1	20020916	ES 2001-1877	20010809
NL 1018741	C1	20020212	NL 2001-1018741	20010810
BE 1013559	A6	20020305	BE 2001-537	20010810
BG 107578	A	20030930	BG 2003-107578	20030221

PRIORITY APPLN. INFO.:
DK 2000-1202 A 20000810
DK 2000-1614 A 20001027
WO 2001-DK520 W 20010730
GB 2001-18579 A3 20010731

AB A solid unit dosage form comprises citalopram, which is prepared by direct compression of a mixture of citalopram base or a salt and excipients, or by filling of the mixture in a hard gelatin capsule. Large **crystals** of a pharmaceutical salt of citalopram and method for the manufacture of large **crystals** are also disclosed. Thus, citalopram-HBr was dissolved in a mixture of MeOH and water at 69°, the solution was cooled to 30°, seeded with the same drug **crystals** and kept at 30° for 24 h, whereupon it was cooled down to 10° within 1 h. The **crystals** were separated by filtration, washed with cold MeOH and dried. Tablets contained citalopram-HBr 20, Prosolv SMCC-90 79.5, and Mg stearate 0.5%.

L8 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:472398 CAPLUS
DOCUMENT NUMBER: 135:61224
TITLE: Method for the preparation and purification of citalopram
INVENTOR(S): Villa, Marcos; Sbrogio, Federico; Dancer, Robert
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001045483	A2	20010628	WO 2001-DK147	20010307
WO 2001045483	A3	20011227		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
NL 1017525	C1	20010426	NL 2001-1017525	20010307
CA 2360303	AA	20010628	CA 2001-2360303	20010307
CA 2360303	C	20030812		
EP 1181713	A2	20020227	EP 2001-913726	20010307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200201166	T1	20021021	TR 2002-20020116	20010307
JP 2003517484	T2	20030527	JP 2001-546230	20010307
DK 174018	B1	20020422	DK 2001-402	20010308
GB 2357763	A1	20010704	GB 2001-5983	20010312
GB 2357763	B2	20020116		
GB 2359811	A1	20010905	GB 2001-15025	20010312
GB 2359811	B2	20030305		
CZ 292200	B6	20030813	CZ 2001-890	20010312
FR 2812877	A1	20020215	FR 2001-3455	20010314
FR 2812877	B1	20030404		
GR 1003874	B1	20020424	GR 2001-100132	20010316
DE 10112829	C1	20020725	DE 2001-10112829	20010316
CH 691535	A	20010815	CH 2001-545	20010322
BE 1013212	A6	20011002	BE 2001-188	20010322
NL 1018360	C1	20011004	NL 2001-1018360	20010622
BE 1013213	A6	20011002	BE 2001-435	20010626
CH 691998	A	20011231	CH 2001-1411	20010726
ES 2170732	A1	20020801	ES 2001-1762	20010727
AU 744112	B1	20020214	AU 2001-65477	20010827
SE 517623	C2	20020625	SE 2001-3045	20010914
SE 2001003045	A	20020623		
BG 106203	A	20020830	BG 2001-106203	20011210
ZA 2001010179	A	20021211	ZA 2001-10179	20011211
NZ 516298	A	20021220	NZ 2001-516298	20011220
HR 2002000004	A1	20030430	HR 2002-4	20020104
US 2002120005	A1	20020829	US 2002-46126	20020108

US 6455710 B2 20020924
PRIORITY APPLN. INFO.: DK 2000-1929 A 20001222
NL 2001-1017525 A 20001222
WO 2001-DK147 W 20010307
GB 2001-5983 A3 20010312
CH 2001-545 A 20010322
OTHER SOURCE(S): CASREACT 135:61224; MARPAT 135:61224
GI



I



II

AB A process for the preparation and purification of citalopram (I) is presented in
which a benzoisofuran derivative [II; Z = iodo, bromo, chloro, CF3(CF2)nSO2O; n = 0-8] is subjected to a cyanide-exchange reaction with a cyanide source (e.g., cuprous cyanide). The resultant crude citalopram is optionally subjected to some initial purification and subsequently treated with an amide or an amide-like group forming agent (e.g., acetic anhydride), the reaction mixture is then subjected to an acid/base wash and/or **crystallization** and recrystn. of citalopram in order to remove the amides formed from the crude citalopram mixture, and the resulting citalopram product is optionally further purified, worked up and isolated as the base or a pharmaceutically acceptable salt.

L8 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

L8 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:607941 CAPLUS
DOCUMENT NUMBER: 133:213148
TITLE: **Crystalline** base of citalopram
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: Ger. Gebrauchsmusterschrift, 17 pp.
CODEN: GGXXFR
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 20007303	U1	20000831	DE 2000-20007303	20000420
GB 2357762	A1	20010704	GB 2001-5982	20000413
GB 2357762	B2	20020130		
NL 1016435	C1	20001106	NL 2000-1016435	20001018
US 2001031784	A1	20011018	US 2000-730490	20001205
DK 173903	B1	20020211	DK 2001-183	20010205
NO 2001000619	A	20010914	NO 2001-619	20010206
FI 2001000225	A	20010914	FI 2001-225	20010207
GR 1003796	B2	20020208	GR 2001-100074	20010212
DE 10108042	A1	20011018	DE 2001-10108042	20010220
DE 20121240	U1	20020808	DE 2001-20121240	20010220
NL 1017413	C1	20010913	NL 2001-1017413	20010221
FR 2806086	A1	20010914	FR 2001-2340	20010221

FR 2806086	B1	20030509			
CH 691477	A	20010731	CH 2001-321	20010222	
CH 691537	A	20010815	CH 2001-580	20010222	
CA 2360287	AA	20010920	CA 2001-2360287	20010228	
CA 2360287	C	20030909			
WO 2001068627	A1	20010920	WO 2001-DK137	20010228	

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BE 1013210	A3	20011002	BE 2001-136	20010228	
EP 1169314	A1	20020109	EP 2001-909568	20010228	
EP 1169314	B1	20020904			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

AU 746664	B2	20020502	AU 2001-37252	20010228	
AU 2001037252	A5	20010913			
EP 1227088	A1	20020731	EP 2002-9350	20010228	
EP 1227088	B1	20030917			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 223396	E	20020915	AT 2001-909568	20010228	
PT 1169314	T	20021129	PT 2001-909568	20010228	
ES 2173054	T3	20021216	ES 2001-1909568	20010228	
TR 200202185	T2	20021223	TR 2002-200202185	20010228	
BR 2001009373	A	20021224	BR 2001-9373	20010228	
JP 2003527383	T2	20030916	JP 2001-567719	20010228	
AT 250050	E	20031015	AT 2002-9350	20010228	
PT 1227088	T	20031231	PT 2002-9350	20010228	
CZ 292077	B6	20030716	CZ 2001-808	20010305	
ES 2159491	A1	20011001	ES 2001-548	20010309	
ES 2159491	B1	20020501			
SE 2001003046	A	20011114	SE 2001-3046	20010914	
SE 517136	C2	20020416			
NO 2002000356	A	20010914	NO 2002-356	20020123	
SE 2002000730	A	20020829	SE 2002-730	20020312	
ZA 2002007148	A	20030423	ZA 2002-7148	20020905	
BG 107065	A	20030530	BG 2002-107065	20020905	
US 2003078442	A1	20030424	US 2002-245824	20020912	
US 2004132808	A1	20040708	US 2003-741553	20031219	

PRIORITY APPLN. INFO.:

DK 2000-402	A	20000313
WO 2000-DK183	W	20000413
DE 2000-10019609	A1	20000420
DE 2001-10108042	IA	20010220
EP 2001-909568	A3	20010228
WO 2001-DK137	W	20010228
US 2002-245824	A1	20020912

AB Citalopram, a selective, centrally acting serotonin reuptake inhibitor useful as an antidepressant, is prepared in high purity from a crude salt or reaction mixture containing citalopram by dissolving the latter in a mixture of H2O and an organic solvent, adding a base, separating and evaporating the organic phase, and **crystallization** from an aprotic solvent. The free base may then be converted to a salt by reaction with the stoichiometric amount of an acid (e.g. HCl, HBr) in a water-miscible solvent (e.g. Me2CO, EtOH), concentration,

and cooling, or by reaction with an excess of acid in Et2O, EtOAc, or CH2Cl2 for formulation as tablets, capsules, powders, syrups, or solns. for injection.

L8 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:204419 CAPLUS
DOCUMENT NUMBER: 128:261968
TITLE: Pharmaceutical composition containing combination of atypical antipsychotic and serotonin reuptake inhibitor for treatment of psychoses
INVENTOR(S): Bymaster, Franklin Porter; Perry, Kenneth Wayne; Tollefson, Gary Dennis
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 830864	A1	19980325	EP 1997-307375	19970922
EP 830864	B1	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 9707967	A	19990304	ZA 1997-7967	19970904
WO 9811897	A1	19980326	WO 1997-US15874	19970909
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9744112	A1	19980414	AU 1997-44112	19970909
AU 719033	B2	20000504		
BR 9711530	A	19990824	BR 1997-11530	19970909
CN 1230886	A	19991006	CN 1997-198113	19970909
NZ 334168	A	20000929	NZ 1997-334168	19970909
JP 2001503031	T2	20010306	JP 1998-514717	19970909
EP 1256345	A1	20021113	EP 2002-16238	19970922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, AL				
AT 231724	E	20030215	AT 1997-307375	19970922
ES 2191152	T3	20030901	ES 1997-307375	19970922
US 6147072	A	20001114	US 1997-935872	19970923
HK 1009755	A1	20031024	HK 1998-110801	19980921
NO 9901381	A	19990322	NO 1999-1381	19990322
KR 2000048518	A	20000725	KR 1999-702422	19990322

PRIORITY APPLN. INFO.: US 1996-26884P P 19960923
WO 1997-US15874 W 19970909
EP 1997-307375 A3 19970922

AB Pharmaceutical compns. containing combination of atypical antipsychotics and serotonin reuptake inhibitors are useful for the treatment of psychoses. Form II olanzapine (I) polymorph was prepared by heating I at 76° for 30 min in Et acetate and **crystallization** Hard gelatin capsules contained I 25, fluoxetin hydrochloride 20, starch 150, and magnesium stearate 10 mg.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 11:49:12 ON 14 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 11:49:18 ON 14 JUL 2004
                E CITALOPRAM/CN
L1              1 S E3
L2              1 S E4
L3              1 S E5
L4              1 S E6
L5              1 S E7

     FILE 'CAPLUS' ENTERED AT 11:50:16 ON 14 JUL 2004
L6           1306 S L1 OR L2 OR L3 OR L4 OR L5
L7        1860643 S CRYSTAL?
L8             13 S L6 AND L7

=>
```